Blog
Published November 3, 2020
Executive Summary
Cell-based therapies are emerging as a promising strategy for cancer and are generating a lot of interest both academically and industrially
To date, cell therapies have been approved in the US by the Food and Drug Administration (FDA) with them showing a lot of promise in a limited number of solid tumors although they have not yet progressed to FDA approval
There have been multiple challenges involved when trying to successfully commercialize the products, but the landscape looks…
Read Now
Blog
Published November 3, 2020
Written by Tom Rutkowski and Patrick Buck…
Read Now
Blog
Published October 15, 2020
Written by Tom Rutkowski, Jay Galli, and Kate Watkins…
Read Now
Blog
Published September 22, 2020
Executive Summary
Although CAR-Ts are on the cutting edge of oncology treatment, they are still only approved for administration following at least two other lines of treatment
Key barriers for CAR-T migration into earlier lines include the complex logistics and site of care restrictions, a lack of comparative 3L+ and 2L clinical trial data, and reimbursement uncertainty in fee-for-service (FFS) Medicare
New opportunities to overcome these hurdles are being pursued in the form of innovative pricing and contracting strategies to…
Read Now
Blog
Published August 25, 2020
Written by Michaela Broadhurst, Olivia Gugliemini, Emily Lewis, and Tom Rutkowski…
Read Now
Blog
Published July 14, 2020
Executive Summary
Digital therapeutics (DTx) represent a novel approach to delivering improved clinical outcomes, but the unstructured nature of today’s DTx access process has presented a major hurdle to broader uptake
Payers are still at very different stages in their acceptance of DTx, and in contrast with traditional pharmaceuticals, buy-in from senior leadership will be an essential part of the top-down decision-making process for DTx prioritization
Pharmacy benefit managers (PBMs) have taken a leadership role in facilitating a pathway for digital therapeutics adoption, and they are likely to…
Read Now
Blog
Published June 2, 2020
Executive Summary
China’s 2019 National Reimbursement Drug List (NRDL) update offers manufacturers key learnings and insights for future NRDL negotiations, particularly with respect to the negotiation tactics used in different disease areas; although in most disease areas the comparative negotiation rule was employed during the 2019 NRDL, the use of a new competitive negotiation rule employed in the hepatitis C disease area characterized the 2019 NRDL negotiations; under this rule, no base price was set and manufacturers were invited to…
Read Now
